<DOC>
	<DOCNO>NCT00828191</DOCNO>
	<brief_summary>Prospective , open , randomize , parallel , multicenter , two-arm trial evaluate efficacy tolerability new progesterone formulation use luteal support IVF ( Progesterone-IBSA ) administer subcutaneously daily dose 25 mg versus Progesterone tablet administer intravaginally 100 mg twice daily total dose 200 mg .</brief_summary>
	<brief_title>Subcutaneous Progesterone Versus Vaginal Progesterone Tablets Luteal Phase Support In Vitro Fertilization ( IVF )</brief_title>
	<detailed_description />
	<mesh_term>Progesterone</mesh_term>
	<criteria>Patient give write informed consent ; BMI &lt; 30 kg/m2 ; Age 18 42 ( upon start COH ) ; &lt; 3 prior ART cycle ( IVF , ICSI relate procedure ) ; Baseline ( day 23 cycling ) FSH &lt; 15 IU/L E2 &lt; 80 pg/mL ; Normal uterine cavity per recent hysterosalpingogram , sonohysterogram hysteroscopic exam ( i.e . polyp protrude submucosal fibroid ) ; Patients must least three retrieve oocyte . Intramural uterine fibroid distort uterine cavity polyp &gt; 1 cm ; Stage III IV endometriosis ( endometriomas ) ; Hydrosalpinges ; History past poor response COH result cancel ART ; Use thawed/donated oocyte ; Use thawed/donated embryo ; Gestational carrier ; Patients affect pathology associate contraindication pregnant ; Hypersensitivity study medication ; Uncontrolled adrenal thyroid dysfunction ; History condition ( i.e . toxic shock syndrome ) would contraindicate use vaginal progesterone product ; History arterial disease ; Patients hepatic impairment ( liver function test &gt; 2x upper limit normal ) ; Patients dermatologic disease ; Patients renal impairment ( estimate creatinine clearance &lt; 60 mL/min/1.73 m2 ) ; Neoplasias ( current ) history neoplasia may responsive progesterone ; High grade cervical dysplasia ; History recurrent pregnancy loss define 3 spontaneous miscarriage , wherein pregnancy develop minimum gestational sac TVUS ; Participation concurrent clinical trial another trial within past 2 month ; Use concomitant medication might interfere study evaluation ; Preimplantation genetic diagnosis/screening</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Luteal support IVF</keyword>
</DOC>